Global News

Jazz Pharmaceuticals to sell women's health business to Meda

Friday, September 7, 2012 10:31 AM

Jazz Pharmaceuticals, a specialty pharmaceutical company based in Dublin, has inked an agreement to sell its women's health business to Meda, an international specialty pharmaceutical company based in Sweden, for $95 million in cash.

More... »

Survey: Product protection rises as a top supply chain concern among healthcare execs

Wednesday, September 5, 2012 02:22 PM

Healthcare executives around the world are investing in their supply chains as they prepare for continued global growth in an increasingly complex and dynamic environment, according to data from the fifth annual UPS "Pain in the (Supply) Chain" healthcare survey, conducted by TNS.

More... »

Marken opens two pharmaceutical depots in New York and Germany

Wednesday, September 5, 2012 11:02 AM

Marken, a global clinical supply chain solutions provider, has completed the first phase of its plan to create a global pharmaceutical depot network that will allow it to satisfy its client's needs for global distribution. Two new depots have been completed: one in Frankfurt, Germany, and one in Farmingdale, New York.

More... »

GE Healthcare launches modular biopharmaceutical factory, KUBio

Wednesday, September 5, 2012 10:26 AM

GE Healthcare, the healthcare business of GE, has launched KUBio, an innovative off-the-shelf, modular factory designed to save manufacturers of biopharmaceuticals both time and money.

More... »

Galapagos subsidiary BioFocus collaborates with Ono on CNS drug discovery

Tuesday, September 4, 2012 12:46 PM

Galapagos’ service division BioFocus and Ono Pharmaceutical have signed a new collaboration agreement focused on discovering novel drugs for CNS disorders. BioFocus will use its drug discovery platform to deliver leads and clinical candidates.

More... »

Expanded IFPMA Code of Practice for pharma industry goes into effect around the world

Tuesday, September 4, 2012 12:44 PM

The International Federation of Pharmaceutical Manufacturers and Associations’ (IFPMA) expanded Code of Practice has taken effect around the world. Governing how companies interact with healthcare professionals, medical institutions and patient organizations, this new code has been adopted by all IFPMA member companies and member associations.

More... »

Merck Serono spin-off Quartz Bio to offer biomarker data analysis

Tuesday, September 4, 2012 12:41 PM

Merck Serono, a division of Merck, has created Quartz Bio, the second spin-off company resulting from its Entrepreneur Partnership Program launched in April. Quartz Bio will offer biomarker data management and exploratory biomarker analysis services to the pharmaceutical industry. Biomarker analysis is a critical step in the drug development process, as it enables the identification of patient profiles most responsive to a given treatment.

More... »

Valeant to acquire Medicis, strengthen dermatology offerings

Tuesday, September 4, 2012 12:36 PM

Montreal-based Valeant Pharmaceuticals International and Medicis Pharmaceutical of Scottsdale, Ariz., have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Medicis for $44 per share in cash. The transaction, which values Medicis' common stock at approximately $2.6 billion, was unanimously approved by the boards of both companies. The $44 price represents a 39% premium to Medicis' closing share price Friday, Aug. 31, the last trading day prior to the announcement, and a 31% premium to the three-month average trading price. The transaction is expected to close in the first half of 2013.

More... »

Assay Depot, Genspace team up for Open Science Challenge

Tuesday, September 4, 2012 12:32 PM

Assay Depot of San Diego and New York-based Genspace have launched the Tri-State Open Science Challenge, a science competition open to citizen scientists and bioartists who want to translate their ideas into reality. Three projects will receive $5,000 in research funding and a one-year membership to Genspace, a community biotechnology laboratory in Brooklyn, NY. One under-18 project will receive $1,000 in research funding.

More... »

Sosei, Novartis tout positive results for phase III QVA149 study in COPD

Thursday, August 30, 2012 03:19 PM

Novartis and Sosei Group, an international biopharmaceutical company based in Japan, released results from the fifth QVA149 (indacaterol maleate / glycopyrronium bromide) phase III study, SPARK, which met its primary endpoint of a reduced rate of moderate-to-severe COPD exacerbations compared to glycopyrronium bromide (Seebri Breezhaler).

More... »